PressSeptember 16, 2025 Reunion Neuroscience upsizes Series A to $133 million after positive trial data
PressSeptember 8, 2025 Cybin completes enrollment in Phase 2 study of CYB004 for generalized anxiety disorder
PressSeptember 4, 2025 JAMA publishes full Phase 2b results for MindMed's MM120 (LSD) in generalized anxiety disorder
PressAugust 26, 2025 Incannex reports positive Phase 2 results for PSX-001 psilocybin therapy in generalized anxiety disorder
PressAugust 25, 2025 AbbVie to acquire Gilgamesh's psychedelic candidate bretisilocin for up to $1.2 billion
PressAugust 18, 2025 Reunion's RE104 hits primary endpoint in Phase 2 RECONNECT postpartum-depression trial
PressAugust 14, 2025 atai Q2 2025: net loss narrows to $27.7M, cash of $95.9M, Beckley combination advancing
PressAugust 13, 2025 Cybin reports fiscal Q1 2026 results; EMBRACE cleared in Europe/UK, $118.7M cash
PressAugust 11, 2025 FDA grants NRx expanded Fast Track for NRX-100 (IV ketamine) in suicidal depression
PressAugust 7, 2025 Forbes coverage amplifies Germany's approval of the EU's first psilocybin access program
PressAugust 7, 2025 GH Research Q2 2025: strong cash position and 73% six-month remission in GH001 extension
PressJuly 31, 2025 Psyence Biomedical and partner PsyLabs report high-purity, GMP-aligned ibogaine extract
PressJuly 28, 2025 atai shares fall as partner Recognify's schizophrenia cognition trial misses primary endpoint
PressJuly 23, 2025 GH Research details global pivotal program for GH001 and full Phase 2b TRD dataset
PressJuly 22, 2025 Reunion publishes RE104 Phase 1 data in the Journal of Clinical Psychopharmacology
